Current Long-Term Pharmacotherapies for the Management of Obesity

Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Obesity & Metabolic Syndrome 2020, 29(2), 96, pp.99-109
Main Authors: Kim, Bo-Yeon, Kang, Seon Mee, Kang, Jee-Hyun, Kim, Kyoung Kon, Kim, Bomtaeck, Kim, Seung Jun, Kim, Yang-Hyun, Kim, Jung-Hwan, Kim, Jae Hyun, Nam, Ga Eun, Park, Ji Yeon, Son, Jang Won, Shin, Hye-Jung, Oh, Tae Jung, Lee, Hyug, Jeon, Eon-Ju, Chung, Sochung, Hong, Yong Hee, Kim, Chong Hwa
Format: Article
Language:English
Subjects:
liraglutide
lorcaserin
naltrexone/bupropion extended-release
obesity
orlistat
phentermine/topiramate extended-release
Review
가정의학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight loss in obese patients with a body mass index of ≥25 kg/m . Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualization treatment of obesity.
ISSN:2508-6235
2508-7576
DOI:10.7570/JOMES20010